Floatz logo

cd22 car-t

B-cell Lymphoma Recurrent

Rong TaoCell therapyPhase 1Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the B-cell Lymphoma Recurrent cohort.

Asset / SponsorPhaseRating
Axicabtagene Ciloleucel
Lyell Immunopharma, Inc.
Phase 4BBB
yy-20394
Jiangsu HengRui Medicine Co., Ltd.
Phase 2B
Recombinant Humanized Monoclonal Antibody Mil62
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2CCC
Abiraterone Acetate
Universität Münster
Phase 2CCC
Enzalutamide
Universität Münster
Phase 2CCC

View all 9 →

Same molecule, other indications

cd22 car-t is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
57 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
50 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →